Semaglutide Taper-Off Schedule: A Reference

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide long-term maintenance hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last October, a 46-year-old project manager named Rachel in Portland told her prescriber something that perfectly captures why this topic matters: "I've lost 38 pounds in seven months and I feel great, but I have no idea what happens if I stop. Nobody's talked to me about an exit plan." Her clinician, to his credit, told her the honest answer: there isn't a single labeled protocol for coming off semaglutide. There's a set of principles, a body of trial data, and a conversation that should happen well before the last injection.

That conversation is what this article is about.

This guide sits inside the broader Semaglutide Long-Term and Maintenance cluster, which is part of the compounded semaglutide pillar guide. If you're here, you've probably already been on the medication for a while and want to understand what a responsible off-ramp looks like.

The STEP-4 Problem: What Actually Happens When You Stop

The most important piece of evidence on this question is the STEP-4 trial, and it's worth understanding exactly what it showed, because patients regularly misinterpret it.

Here's the setup: patients completed a 20-week open-label run-in on semaglutide 2.4 mg. Then they were randomized. Half continued the drug. Half switched to placebo. The placebo group regained roughly two-thirds of the weight they had lost over the following 48 weeks. The group that stayed on the drug continued to lose a modest amount of additional weight.

The knee-jerk reading of this is "the medication stops working when you stop taking it." That's not quite right. The better reading is that obesity is a chronic metabolic condition, and when you remove pharmacologic support, the underlying biology reasserts itself. This is the same thing that happens when someone with hypertension stops their blood pressure medication. Nobody calls that a failure of the drug. They call it the natural history of the disease.

Here's the thing: this data point should shape the entire taper conversation. A semaglutide taper off schedule isn't about "weaning your body off a drug." It's about giving yourself and your clinician time to see what your appetite regulation, your behavioral patterns, and your weight trajectory look like at progressively lower doses before you're flying without a net.

Why Taper at All (Since There's No Withdrawal Syndrome)

Let's be precise about this. Semaglutide does not produce a pharmacologic withdrawal syndrome. You will not have shakes, seizures, rebound nausea, or any of the phenomena associated with abrupt discontinuation of, say, benzodiazepines or opioids. The molecule has a half-life of roughly 165 to 184 hours. It clears your system gradually over several weeks on its own.

So why not just stop?

Because the practical experience is that appetite returns, and it can return with force. If you've been on a therapeutic dose for six months or longer, your brain has recalibrated to a different satiety baseline. Pulling the rug out all at once means the hunger signals come back before you've had a chance to test whether your new eating patterns and movement habits can hold without pharmaceutical support. A stepwise taper turns that sudden shock into a series of smaller, more manageable tests.

Think of it like gradually removing the training wheels rather than yanking them both off at the top of a hill.

A Common Taper Structure (Not a Protocol)

There is no labeled, FDA-sanctioned taper schedule for semaglutide. What exists is clinical convention, which converges on a pattern that basically mirrors the original titration in reverse.

For a patient currently at the 2.4 mg maintenance dose, the typical approach looks something like:

Step down to 1.7 mg for four to eight weeks
Step down to 1.0 mg for four to eight weeks
Step down to 0.5 mg for four to eight weeks
Discontinue

At each plateau, the clinician and patient evaluate a short checklist: How much has hunger returned? Is weight stable, drifting up, or still declining? Are the lifestyle habits (meal prep, activity level, sleep) holding at this lower dose? The pace can be compressed or stretched depending on what those check-ins reveal. Some patients will step down every four weeks and do fine. Others will need two months at a given dose before they feel stable enough to go lower.

I want to be direct about something: the four-to-eight-week intervals are a clinical convention, not a finding from a randomized trial. No one has run a head-to-head trial comparing different taper speeds. Clinicians use this timeline because it roughly matches the time needed to reach a new pharmacokinetic steady state at each dose and because it's long enough to observe meaningful behavioral signals.

Restarting After a Gap

Life happens. Insurance lapses. Supply shortages hit. Some patients take a break and want to come back. The standard clinical approach is to not jump back to your prior maintenance dose. Instead, you restart the titration from a lower step (typically 0.25 mg or 0.5 mg) and work your way back up.

This serves two purposes. First, the slow-gastric-emptying effect that causes most of the GI side effects (nausea, especially) is dose-dependent, and your tolerance resets after a multi-month gap. Second, it gives your prescriber a chance to reassess your clinical picture before reaching the higher doses. Your metabolic status, medication list, and health goals may have shifted during the break.

The Chronic-Therapy Question

The trial evidence from STEP-1, STEP-3, STEP-4, SELECT, and LEADER collectively supports a framing that many patients find uncomfortable: semaglutide, for many people, works best as a chronic therapy for a chronic condition.

That doesn't mean every patient stays on it forever. It means the default assumption should be long-term use, and the decision to taper off should be an active, eyes-open clinical choice rather than a passive drift driven by cost, inconvenience, or a vague sense that "I should be able to do this on my own." Some patients will taper off successfully, maintain their losses through behavioral changes, and never need the medication again. Others will discover during the taper that their hunger regulation requires ongoing pharmacologic support. Both outcomes are legitimate.

The most common mistake I see in patient forums is treating a taper as a graduation. It can be. But it can also be a diagnostic test that tells you something important about where you stand.

Compounded Semaglutide: Same Molecule, Different Regulatory Frame

A note for patients on compounded semaglutide specifically, since that's the context for most readers here. The active ingredient is the same molecule used in Wegovy and Ozempic. The clinical evidence from the STEP and SUSTAIN trial programs applies to the molecule itself.

The difference is regulatory. Compounded semaglutide is prepared by a licensed compounding pharmacy under a clinician prescription, operating under the 503A or 503B compounding framework. It is not FDA-approved. The compounded preparation has not been independently tested in randomized controlled trials at the scale of the branded products. This distinction matters for informed consent, even though the pharmacology is, by definition, the same.

What matters more than the label on the vial is the quality of the clinical relationship behind it. A program that supports honest conversation about tapering, responds to side effects with appropriate dose adjustments, and provides structured follow-up between refills is worth more than slick branding with thin clinical infrastructure underneath.

Four Misconceptions That Keep Coming Up

"Side effect intensity predicts better results." Trial data from STEP-1 and STEP-3 do not support this. Patients with mild GI tolerability and patients who struggled with nausea both achieved clinically meaningful weight loss. Suffering through worse nausea does not buy you more efficacy.

"Compounded semaglutide has the same regulatory status as Wegovy." It does not. Compounding pharmacies operate under a fundamentally different regulatory framework. Compounded preparations are not FDA-approved.

"The medication does all the work." STEP-3, which paired semaglutide with an intensive behavioral intervention, produced greater mean weight loss than STEP-1, which used the medication with standard lifestyle counseling. Lifestyle effort is additive and, for long-term maintenance, probably essential.

"Stopping returns you to baseline." STEP-4 documented partial regain, not total regain, over 48 weeks. The chronic biology of weight regulation pushes back toward a higher set point, but the trajectory depends heavily on what behavioral infrastructure you've built while on therapy.

Adjacent Reading

Where This Fits

This article is part of the Semaglutide Long-Term and Maintenance cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Is tapering off semaglutide medically necessary?

There is no pharmacologic withdrawal syndrome with semaglutide, so tapering isn't necessary in the way it is with, say, corticosteroids. But most obesity medicine clinicians recommend it because a gradual step-down lets you and your prescriber observe how your appetite regulation, weight, and habits respond at each lower dose before the medication is fully out of your system.

What happens to weight after stopping semaglutide?

STEP-4 showed that patients who switched from active semaglutide to placebo at week 20 regained roughly two-thirds of the weight they had lost over the following 48 weeks. The degree of regain in practice depends on the behavioral and lifestyle patterns a patient has established during treatment.

Can I restart semaglutide after a long break?

Yes, but clinicians typically restart the titration from a lower dose (often 0.25 mg or 0.5 mg) rather than resuming at the prior maintenance dose. This rebuilds GI tolerability and gives the prescriber a chance to reassess your clinical picture.

How long does a full taper typically take?

For a patient stepping down from 2.4 mg through each lower dose level at four-to-eight-week intervals, a complete taper takes roughly three to six months. The pace is adjusted based on individual response at each step.

Is the taper schedule the same for compounded semaglutide as for Wegovy?

The molecule is the same, so the pharmacologic principles are the same. Compounded preparations may come in different concentration formats, which can affect how dose reductions are measured practically, but the clinical logic of a stepwise taper applies equally.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.